Asthma and lower airway diseaseSeasonal risk factors for asthma exacerbations among inner-city children
Section snippets
Overview
This analysis examines risk factors for asthma exacerbations in 400 control group participants from 2 recent studies from the Inner-City Asthma Consortium: the Asthma Control Evaluation (ACE) study (n = 253)4 and the Inner City Anti-IgE Therapy for Asthma (ICATA) study (n = 147).18 Seasonal and year-round predictors are considered by using both univariate and multivariate analytic techniques. Of note, in both the ACE and ICATA studies, all participants (including control subjects) were given
Participants' characteristics
For more information on participants' characteristics, see Table I. The 400 participants from the ACE and ICATA study control treatment groups included in these analyses were typically low income (55.5% with income <$15,000), minority (59% black and 30% Hispanic), and overweight (median body mass index [BMI] percentile at screening, 88.8%). Their median age was 13 years. In the 6 months before study entry, 16.8% were hospitalized for asthma. At study screening, the mean Asthma Control Test
Discussion
Our analysis of exacerbations on a seasonal basis derived from the control treatment arms of the ACE4 and ICATA18 studies from the Inner-City Asthma Consortium reveals a number of important factors relevant to the identification of inner-city children at high risk for asthma exacerbations. First, our ability to predict exacerbations based on commonly used characteristics of patients varies greatly by season. In the fall these factors predict 30.5% of the variance, a highly clinically
References (34)
- et al.
Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma
J Allergy Clin Immunol
(2012) - et al.
Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial
Lancet
(2008) - et al.
Understanding the seasonal pattern of childhood asthma: results from the National Cooperative Inner-City Asthma Study (NCICAS)
J Pediatr
(2002) - et al.
The September epidemic of asthma exacerbations in children: a search for etiology
J Allergy Clin Immunol
(2005) - et al.
Role of viral respiratory infections in asthma and asthma exacerbations
Lancet
(2010) - et al.
Understanding the September asthma epidemic
J Allergy Clin Immunol
(2007) - et al.
Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children
J Allergy Clin Immunol
(2008) - et al.
Risk factors and predictive clinical scores for asthma exacerbations in childhood
Chest
(2010) - et al.
Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma
J Allergy Clin Immunol
(2009) - et al.
Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents
J Allergy Clin Immunol
(2012)
The role of rhinovirus in asthma exacerbations
J Allergy Clin Immunol
Prevalence of viral respiratory tract infections in children with asthma
J Allergy Clin Immunol
Overweight/obesity and risk of seasonal asthma exacerbations
J Allergy Clin Immunol Pract
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial
J Allergy Clin Immunol
Guideline-recommended fractional exhaled nitric oxide is a poor predictor of health-care use among inner-city children and adolescents receiving usual asthma care
Chest
The role of symptomatic colds in asthma exacerbations: influence of outdoor allergens and air pollutants
J Allergy Clin Immunol
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire
Respir Med
Cited by (0)
This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract nos. NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, and HHSN272201000052I. Additional support was provided by the National Center for Research Resources, National Institutes of Health, under grants RR00052, M01RR00533, UL1 RR024982, M01RR00071, 5M01RR020359-04, 1UL1RR025771, 1UL1RR025780, 1UL1RR024156, UL1RR031988, UL1RR025741, and UL1TR000451. Lincoln Diagnostics provided the Multi-Test, and GlaxoSmithKline (GSK) provided study drug for Asthma Control Evaluation study participants. Novartis Pharmaceuticals provided study drug under a clinical trial agreement with the University of Wisconsin–Madison, Dey Pharma provided EpiPens, and SC Johnson provided household pest control for Inner City Anti-IgE Therapy for Asthma study participants. None of these companies had a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit for publication.
Disclosure of potential conflict of interest: S. J. Teach has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and Novartis; is employed by the Children's National Health System; has received research support from the NIH/NIAID, the Kohls Foundation, the Stewart Foundation, and PCORI; and has received royalties from UpToDate. S. J. Szefler has received research support and travel support from the NIAID Inner-City Asthma Consortium; has received consultancy fees from Merck, Boehringer Ingelheim, GlaxoSmithKline, and Genentech; has received research support from GlaxoSmithKline; has received lecture fees from Merck; and has a patent with the National Heart, Lung, and Blood Institute (NHLBI) CARE Network. H. E. Mitchell and A. Calatroni has received research support from the NIH/NIAID. J. Wildfire and G. R. Bloomberg have received research support and travel support from the NIH/NIAID. C. M. Kercsmar has received research support from the NIH, is a board member for GlaxoSmithKline, and has received royalties from UpToDate. A. H. Liu has received lecture fees from Merck Sharp & Dohme and is a Data Safety Committee member for GlaxoSmithKline. M. M. Makhija has received travel support from the NIAID Inner-City Asthma Consortium. E. Matsui has received research support from the NIH, is a board member for the US Environmental Protection Agency Science Advisory Board, and is employed by Johns Hopkins University. W. Morgan has received research support and travel support from the NIAID/NIH and the University of Wisconsin-Madison; has received consultancy fees from Genentech and the Cystic Fibrosis Foundation; is employed by the University of Arizona; has received research support from AsthmaNet NIH/NHLBI, the Cystic Fibrosis Foundation, Mt Sinai College of Medicine, and the NIH/NHLBI; and has received lecture fees from the American Thoracic Society and the American College of Chest Physicians. G. O'Connor has received research support from the NIH. W. W. Busse has been supported by the NHLBI/NIH; is a board member for Merck; has received consultancy fees from Novartis, GlaxoSmithKline, Genentech, Roche, Pfizer, Boston Scientific, Circassia, ICON, AstraZeneca, Sanofi, Amgen, MedImmune, NeoStem, Takeda, and Boehringer Ingelheim; has received research support from the NIAID/NIH and the NHLBI/NIH; and has received royalties from Elsevier. P. J. Gergen declares that he has no relevant conflicts of interest.